Company Badge
USPTO Data Jan 1 1976 - Oct 13 2026
5 Patents
#120 in Durham, NC
#1,123 in North Carolina
#51,620 in US
Emergo Therapeutics, Inc.
Forward Citations = 16
3 inventors:
Durham, NC, United States of America
Emergo Therapeutics, Inc.
EPO Patents = 1
Forward Citations = 16
Loading Chart...
Loading Chart...
3 inventors (with patents filed for the assignee):
Robin Parish Hyde-Deruyscher (5 out of 9 patents)
Nancy Harlan Hyde-DeRuyscher (4 out of 5 patents)
Elicia Kristine Hyde-DeRuyscher (4 out of 5 patents)
5 patents:
3. 10501527 - Mast cell stabilizers for treatment of hypercytokinemia and viral infection (2019-12-10),
Company Overview
Emergo Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for infectious diseases. With a strong commitment to research and development, Emergo aims to bring new therapies to market that address unmet medical needs and improve patient outcomes. The company's pipeline includes promising candidates for various infectious diseases, with a focus on finding solutions for antibiotic-resistant strains.
Profile summary synthesized from public USPTO records and patent filings.
IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Emergo Therapeutics, Inc.. Retrieved from https://idiyas.com/company/emergo-therapeutics
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
1 patent (EPO):
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]